Skip to main content

Table 1 Main characteristics of study population according to regimen started after switch

From: Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

 

All study population

Triple

Dual

Mono

p value

Patients’ characteristics

(n = 1241)

(n = 1073)

(n = 104)

(n = 64)

Male gender, n (%)

988 (79.6%)

853 (79.5%)

86 (82.7%)

49 (76.6%)

0.612

Age, median (IQR)

43 (36–50)

42 (35–50)

45 (38–51)

44 (38–49)

0.065

Mode of HIV transmission, n (%)

 Heterosexual

534 (43.0%)

474 (44.2%)

40 (38.5%)

20 (31.3%)

0.025

 Injection drug use

100 (8.1%)

92 (8.6%)

5 (4.8%)

3 (4.7%)

 Men who have sex with men

533 (42.9%)

440 (41.0%)

54 (51.9%)

39 (60.9%)

 Other/unknown

74 (6.0%)

67 (6.2%)

5 (4.8%)

2 (3.1%)

Migrants, n (%)

151 (12.2%)

136 (12.7%)

8 (7.7%)

7 (10.9%)

0.317

Previous AIDS event, n (%)

161 (130%)

152 (14.2%)

8 (7.7%)

1 (1.6%)

0.004

Years of HIV infection, median (IQR)

3.4 (1.6–6.3)

3.3 (1.6–6.3)

3.3 (1.6–6.5)

4.2 (2.1–6.1)

0.472

HCV Ab, n (%)

 Negative

1057 (85.2%)

908 (84.6%)

88 (84.6%)

61 (95.3%)

0.197

 Positive

120 (9.7%)

109 (10.2%)

10 (9.6%)

1 (1.6%)

 Unknown

64 (5.1%)

56 (5.2%)

6 (5.8%)

2 (3.1%)

CD4 before cART start, n (%)

  < 200

368 (29.7%)

334 (31.1%)

24 (23.1%)

10 (15.6%)

0.047

 201–350

399 (32.2%)

344 (32.1%)

29 (27.9%)

26 (40.6%)

 351–500

307 (24.7%)

258 (24.0%)

30 (28.9%)

19 (29.7%)

 500+

143 (11.5%)

116 (10.8%)

18 (17.3%)

9 (14.1%)

 Missing

24 (1.9%)

21 (2.0%)

3 (2.8%)

HIV RNA before cART start, n (%)

  < 20,000

337 (27.2%)

279 (26.0%)

37 (35.5%)

21 (32.8%)

0.385

 20,000–100,000

410 (33.0%)

358 (33.3%)

30 (28.9%)

22 (34.4%)

 100,000–250,000

235 (18.9%)

207 (19.3%)

18 (17.3%)

10 (15.6%)

 250,000+

233 (18.8%)

208 (19.4%)

15 (14.4%)

10 (15.6%)

 Missing

26 (2.1%)

21 (2.0%)

4 (3.9%)

1 (1.6%)

CD4 at switch, median (IQR)

  < 350

219 (17.7%)

199 (18.6%)

14 (13.5%)

6 (9.4%)

0.008

 350–500

285 (23.0%)

255 (23.8%)

23 (22.1%)

7 (10.9%)

 500+

737 (59.3)

619 (57.6%)

67 (64.4%)

51 (79.7%)

CD4 at switch, median (IQR)

554 (402–740)

547 (394–729)

600 (426–819)

614 (506–807)

0.012

CD8 at switch, median (IQR)

824 (600–1118)

832 (601–1121)

797 (587–1124)

768 (597–1009)

0.467

CD4/CD8 ratio at switch, median (IQR)

0.69 (0.45–0.98)

0.67 (0.44–0.97)

0.78 (0.51–1.10)

0.83 (0.58–1.09)

0.008

CD4/CD8 ratio at switch > = 1, n (%)

303 (24.4%)

256 (23.9%)

29 (27.9%)

18 (28.1%)

0.513

Months of antiretroviral exposure, median (IQR)

18 (9–34)

17 (8–35)

18 (12–36)

20 (12–31)

0.184

Months of viral suppression, median (IQR)

21 (11–39)

21 (10–39)

20 (12–37)

20 (13–34)

0.824

Reason for switch, n (%)

 Toxicity

330 (26.6%)

294 (27.4%)

27 (26.0%)

9 (14.1%)

< 0.001

 Simplification

493 (39.6%)

407 (38.0%)

42 (40.4%)

44 (68.7%)

 Patient’s decision

18 (1.5%)

17 (1.6%)

0 (0.0%)

1 (1.6%)

 Other

387 (31.2%)

346 (32.2%)

31 (29.8%)

10 (15.6%)

 Missing

13 (1.1%)

9 (0.8%)

4 (3.8%)

0 (0.0%)